{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-053933","form_type":"8-K","ticker":"NMRA","cik":"0001885522","company_name":"Neumora Therapeutics, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.091669+00:00","generated_at":"2026-06-02T20:53:31.927988+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Neumora Q1 net loss $53.7M; navacaprant Phase 3 MDD data on track for Q4 2024; NMRA-266 clinical hold with FDA","bullets":["Net loss of $53.7M in Q1 2024 vs $35.6M in Q1 2023; R&D expense $45.8M, G&A $14.3M.","Cash, cash equivalents and marketable securities of $423.0M; expected to fund operations into 2026.","Topline Phase 3 data from navacaprant KOASTAL-1 in MDD expected Q4 2024; Phase 2 bipolar depression trial to start Q2 2024.","NMRA-511 Phase 1 complete; Phase 1b in Alzheimer's agitation to start Q2 2024 with data in 2025.","FDA placed clinical hold on NMRA-266 Phase 1 study; company working to resolve; additional M4 PAM IND expected 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-053933","json":"https://secwatch.observer/filing/0000950170-24-053933.json","markdown":"https://secwatch.observer/filing/0000950170-24-053933.md","text":"https://secwatch.observer/filing/0000950170-24-053933.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1885522/000095017024053933/0000950170-24-053933-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1885522/000095017024053933/nmra-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T20:53:31.927988+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5e4336816c8a57ba219e2c32f7b904838d61e25f","claim":"Neumora Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income net loss of $53.7 million.","evidence_excerpt":"announced its financial results for the first quarter ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017024053933/0000950170-24-053933-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"net loss of $53.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}